Expert Ratings For Rhythm Pharmaceuticals
Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter:
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
DARK SECRETS: 2 | Rare Historical Photos
Rhythm Pharmaceuticals Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q4 sales of $1.82 million. Earnings fell to a loss of $42.87 million, resulting in a 22.1% decrease from last quarter.
Benzinga ·
Rhythm Pharmaceuticals: Q4 Earnings Insights
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
International Business Times UK
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
